<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181011</url>
  </required_header>
  <id_info>
    <org_study_id>1235.30</org_study_id>
    <nct_id>NCT01181011</nct_id>
  </id_info>
  <brief_title>Telmisartan, Amlodipine and Combination in Healthy Subjects</brief_title>
  <official_title>A Single-centre, Randomized, Open-label, Three-period Crossover Pharmacokinetic Study of 80 mg Telmisartan / 5 mg Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To determine the pharmacokinetic profile of 80 mg telmisartan / 5 mg amlodipine (T80/A5) dose
      combination after single dose in healthy Chinese subjects.

      To determine whether a pharmacokinetic interaction exists between telmisartan and amlodipine,
      following single doses of 80mg telmisartan (T80), and 5 mg amlodipine (A5) tablet alone and
      in combination, in healthy Chinese subjects.

      To evaluate the safety and tolerability of T80 and A5 alone and in combination in healthy
      Chinese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz)</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUC_0-∞) of Telmisartan</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum Observed Plasma Concentration (Cmax) of Telmisartan</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC_0-tz of Amlodipine</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC_0-∞ of Amlodipine</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Amlodipine</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days of wash-outs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Attain Cmax (Tmax) of Telmisartan</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Rate Constant in Plasma (λz) of Telmisartan</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
    <description>reflect the speed of drug elimination in vivo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time of Telmisartan in the Body After Oral Administration (MRT_po)</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life (t_½) of Telmisartan</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of Telmisartan in Plasma Following Extravascular Administration (CL/F)</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase λz Following an Extravascular Administration (V_z/F) of Telmisartan</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Amlodipine</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz of Amlodipine</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT_po of Amlodipine</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t_½ of Amlodipine</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Amlodipine</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V_z/F of Amlodipine</measure>
    <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Treatment Emergent Adverse Event</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Findings in Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>amlodipine/telmisartan/combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine/telmisartan/combination</intervention_name>
    <description>patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.</description>
    <arm_group_label>amlodipine/telmisartan/combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Healthy males and females

          2. Aged between 18 and 45 years

          3. Body weight more than 50Kg , and Body Mass Index (BMI ) between 19 and 24 kg/m2

        Exclusion criteria

          1. Any finding of the medical examination deviating from normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Surgery of the gastrointestinal tract (except appendectomy)

          5. Diseases of the central nervous system or psychiatric disorders or neurological
             disorders

          6. History of relevant orthostatic hypotension, fainting spells or blackouts.

          7. Chronic or relevant acute infections

          8. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          9. Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

         10. Use of drugs which might reasonably influence the results of the trial

         11. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         12. Smoker

         13. Inability to refrain from smoking during 24 hours prior to dosing and during the trial

         14. Alcohol abuse or inability to stop alcoholic beverages for 24 hours prior to dosing
             and during the trial

         15. Drug abuse

         16. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         17. Excessive physical activities (within one week prior to administration or during the
             trial)

         18. Any laboratory value outside the reference range that is of clinical relevance

         19. Inability to comply with dietary regimen of trial site

         20. A history of additional risk factors for torsade de pointes

         21. Any history of relevant low blood pressure

         22. Supine blood pressure at screening of systolic &lt;110 mm Hg and diastolic &lt; 60 mm Hg

         23. History of urticaria

         24. History of angioneurotic edema 25 Pregnancy / positive pregnancy test, or planning to
             become pregnant during the study or within 1 month of study completion

        26. No adequate contraception during the study and until 1 month of study completion 27.
        Lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.30.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <results_first_submitted>November 21, 2011</results_first_submitted>
  <results_first_submitted_qc>April 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2012</results_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Telmisartan 80mg</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Telmisartan 80mg,Amlodipine 5mg</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Amlodipine 5mg</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz)</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for AUC_0-tz of Telmisartan</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz)</title>
          <population>All patients with values for AUC_0-tz of Telmisartan</population>
          <units>ng·h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3200" spread="74.7"/>
                    <measurement group_id="O2" value="2940" spread="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence</non_inferiority_desc>
            <p_value>0.0107</p_value>
            <p_value_desc>The p-value is for the ratio being outside the interval 0.8 to 1.25.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>gMean Ratio</param_type>
            <param_value>109.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.06</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>99.45</ci_lower_limit>
            <ci_upper_limit>119.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUC_0-∞) of Telmisartan</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for AUC_0-∞ of Telmisartan</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUC_0-∞) of Telmisartan</title>
          <population>All patients with values for AUC_0-∞ of Telmisartan</population>
          <units>ng·h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3420" spread="82.5"/>
                    <measurement group_id="O2" value="3140" spread="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence</non_inferiority_desc>
            <p_value>0.0139</p_value>
            <p_value_desc>The p-value is for the ratio being outside the interval 0.8 to 1.25.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>gMean Ratio</param_type>
            <param_value>109.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.06</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.96</ci_lower_limit>
            <ci_upper_limit>120.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Maximum Observed Plasma Concentration (Cmax) of Telmisartan</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for Cmax of Telmisartan</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Observed Plasma Concentration (Cmax) of Telmisartan</title>
          <population>All patients with values for Cmax of Telmisartan</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461" spread="59.9"/>
                    <measurement group_id="O2" value="480" spread="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence</non_inferiority_desc>
            <p_value>0.0126</p_value>
            <p_value_desc>The p-value is for the ratio being outside the interval 0.8 to 1.25.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>gMean Ratio</param_type>
            <param_value>97.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.09</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.643</ci_lower_limit>
            <ci_upper_limit>112.472</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC_0-tz of Amlodipine</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for AUC_0-tz of Amlodipine</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>AUC_0-tz of Amlodipine</title>
          <population>All patients with values for AUC_0-tz of Amlodipine</population>
          <units>ng·h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206" spread="28.6"/>
                    <measurement group_id="O2" value="192" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence</non_inferiority_desc>
            <p_value>0.0011</p_value>
            <p_value_desc>The p-value is for the ratio being outside the interval 0.8 to 1.25.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>gMean Ratio</param_type>
            <param_value>109.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.04</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>102.87</ci_lower_limit>
            <ci_upper_limit>117.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC_0-∞ of Amlodipine</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for AUC_0-∞ of Amlodipine</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>AUC_0-∞ of Amlodipine</title>
          <population>All patients with values for AUC_0-∞ of Amlodipine</population>
          <units>ng·h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225" spread="27.1"/>
                    <measurement group_id="O2" value="210" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence</non_inferiority_desc>
            <p_value>0.0006</p_value>
            <p_value_desc>The p-value is for the ratio being outside the interval 0.8 to 1.25.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>gMean Ratio</param_type>
            <param_value>108.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>102.1</ci_lower_limit>
            <ci_upper_limit>116.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Amlodipine</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days of wash-outs</time_frame>
        <population>All patients with values for Cmax of Amlodipine</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Amlodipine</title>
          <population>All patients with values for Cmax of Amlodipine</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="21.7"/>
                    <measurement group_id="O2" value="4.43" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence</non_inferiority_desc>
            <p_value>0.000</p_value>
            <p_value_desc>The p-value is for the ratio being outside the interval 0.8 to 1.25.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>gMean Ratio</param_type>
            <param_value>106.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.9</ci_lower_limit>
            <ci_upper_limit>112.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Attain Cmax (Tmax) of Telmisartan</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for tmax of Telmisartan</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Attain Cmax (Tmax) of Telmisartan</title>
          <population>All patients with values for tmax of Telmisartan</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="0.58" lower_limit="0.5" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.16" spread="0.76" lower_limit="0.5" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Rate Constant in Plasma (λz) of Telmisartan</title>
        <description>reflect the speed of drug elimination in vivo</description>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for λz of Telmisartan</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant in Plasma (λz) of Telmisartan</title>
          <description>reflect the speed of drug elimination in vivo</description>
          <population>All patients with values for λz of Telmisartan</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0305" spread="0.0114"/>
                    <measurement group_id="O2" value="0.0323" spread="0.0124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time of Telmisartan in the Body After Oral Administration (MRT_po)</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for MRT_po of Telmisartan</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time of Telmisartan in the Body After Oral Administration (MRT_po)</title>
          <population>All patients with values for MRT_po of Telmisartan</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="4.8"/>
                    <measurement group_id="O2" value="18.4" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-life (t_½) of Telmisartan</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for t_½ of Telmisartan</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life (t_½) of Telmisartan</title>
          <population>All patients with values for t_½ of Telmisartan</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" spread="13.7"/>
                    <measurement group_id="O2" value="25.0" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance of Telmisartan in Plasma Following Extravascular Administration (CL/F)</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for CL/F of Telmisartan</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance of Telmisartan in Plasma Following Extravascular Administration (CL/F)</title>
          <population>All patients with values for CL/F of Telmisartan</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" spread="21.6"/>
                    <measurement group_id="O2" value="37.3" spread="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase λz Following an Extravascular Administration (V_z/F) of Telmisartan</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for V_z/F of Telmisartan</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg</title>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase λz Following an Extravascular Administration (V_z/F) of Telmisartan</title>
          <population>All patients with values for V_z/F of Telmisartan</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1021" spread="697"/>
                    <measurement group_id="O2" value="1135" spread="1018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Amlodipine</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for tmax of Amlodipine</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Amlodipine</title>
          <population>All patients with values for tmax of Amlodipine</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.88" spread="1.74" lower_limit="6.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="7.20" spread="1.63" lower_limit="6.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>λz of Amlodipine</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for λz of Amlodipine</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>λz of Amlodipine</title>
          <population>All patients with values for λz of Amlodipine</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0305" spread="0.0114"/>
                    <measurement group_id="O2" value="0.0323" spread="0.0124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRT_po of Amlodipine</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for MRT_po of Amlodipine</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>MRT_po of Amlodipine</title>
          <population>All patients with values for MRT_po of Amlodipine</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="7.0"/>
                    <measurement group_id="O2" value="43.7" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t_½ of Amlodipine</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for t_½ of Amlodipine</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>t_½ of Amlodipine</title>
          <population>All patients with values for t_½ of Amlodipine</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="7.6"/>
                    <measurement group_id="O2" value="38.6" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F of Amlodipine</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for CL/F of Amlodipine</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>CL/F of Amlodipine</title>
          <population>All patients with values for CL/F of Amlodipine</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="6.3"/>
                    <measurement group_id="O2" value="25.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>V_z/F of Amlodipine</title>
        <time_frame>3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs</time_frame>
        <population>All patients with values for V_z/F of Amlodipine</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>V_z/F of Amlodipine</title>
          <population>All patients with values for V_z/F of Amlodipine</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1241" spread="313"/>
                    <measurement group_id="O2" value="1353" spread="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Treatment Emergent Adverse Event</title>
        <time_frame>4 weeks</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg</title>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Treatment Emergent Adverse Event</title>
          <population>Treated set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Findings in Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities</title>
        <time_frame>4 weeks</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 80mg, Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80mg</title>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Findings in Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities</title>
          <population>Treated set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ECG abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vital signs abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical finding abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory finding abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan 80mg, Amlodipine 5mg</title>
        </group>
        <group group_id="E2">
          <title>Telmisartan 80mg</title>
        </group>
        <group group_id="E3">
          <title>Amlodipine 5mg</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Pharmaceuticals</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>800-542-6257 ext Option 4</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

